Donald Ebersole
Family Medicine · Everett, WANPI 1932179587
Payments from drug & device makers
Across 118 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$461
- Novo Nordisk$294
- Pfizer$280
- Lilly USA, LLC$233
- Johnson & Johnson$204
- Amgen$165
- plus $740 from 18 others
What the payments were for
- Food & beverage$2,377100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $461 |
| Novo Nordisk | 12 | $294 |
| Pfizer | 12 | $280 |
| Lilly USA, LLC | 10 | $233 |
| Johnson & Johnson | 14 | $204 |
| Amgen | 5 | $165 |
| Novartis | 6 | $100 |
| GSK | 5 | $75 |
| Merck | 5 | $71 |
| Abbott | 4 | $65 |
| Bayer | 3 | $56 |
| AstraZeneca | 3 | $49 |
| Biogen | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Insulet Corporation | 2 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| Dexcom, Inc. | 2 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Si-bone, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,377 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $7,634 |
| JanuviaSitagliptin Phosphate | 25 | $6,905 |
| Entacapone | 14 | $3,484 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 39 | $1,857 |
| Oxcarbazepine | 15 | $1,319 |
| Atorvastatin Calcium | 75 | $1,139 |
| Solifenacin Succinate | 13 | $1,076 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $947 |
| Rosuvastatin Calcium | 63 | $905 |
| Gabapentin | 48 | $752 |
| Midodrine Hcl | 21 | $722 |
| Metformin Hcl ErMetformin Hcl | 16 | $705 |
| Tizanidine Hcl | 27 | $687 |
| Levothyroxine Sodium | 54 | $609 |
| Potassium Chloride | 27 | $578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $31 | $7,63413 claims |
| MerckJanuvia | $71 | $6,90525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Everett
- David LindstromEverett$37K
- Marlon BalauagEverett$20K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.